Gujarat Themis Biosyn Announces 44th AGM, Annual Report & Future Plans
The AGM and annual report provide important information to shareholders, and the company's growth plans could have a moderate impact on its future performance.
The announcement contains positive financial results, expansion plans, and future growth strategies, indicating a positive outlook for the company.
* Gujarat Themis Biosyn Limited (GUJTHEM) will hold its 44th Annual General Meeting (AGM) on 12th September, 2025, to discuss the annual report for the financial year ended 31st March, 2025, and other important matters. * Key highlights from the Chairman's message: * The company reported revenue of ₹150.8 crore, EBITDA of ₹68.8 crore, and PAT of ₹48.8 crore for the year ended 31st March, 2025. * Phase 1 of the new R&D facility is completed, with further expansions on track. * A dedicated API block has been completed, with commercial production expected to commence soon. * Additional fermentation capacity is being created to support the scale-up of new molecules. * The company aims to expand its product portfolio with new intermediates and APIs. * The AGM will also cover: * Re-appointment of Dr. Dinesh S. Patel as a Director. * Declaration of dividend on equity shares for FY25. * Ratification of remuneration of the Cost Auditor for FY26 at ₹50,000 plus expenses. * Appointment of M/s. KRS AND Co. as Secretarial Auditor for five years, from FY26 to FY30. * Appointment and re-designation of Dr. Sachin D. Patel as Managing Director for five years, effective 1st July, 2025. * Approval for payment of commission of ₹66 lakh to Dr. Dinesh S. Patel and Dr. Sachin D. Patel as Non-Executive Directors. * Appointment of Mr. Nihar Ajay Parikh as an Independent Director for a term of five years. * Approval for payment of commission to Independent Directors, capped at 1% of net profits.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under agm-egm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.